TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
$AnaptysBio (ANAB.US)$ NEWS Anaptys Announces Positive Top-L...
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence of infections, no cases of DRESS or GBS reported, and low incidence of anti-drug antibodies detected
Plan to out-license imsidolimab in 2024 to bring the therapy to patients with GPP
Negative
Some patients who received placebo in GEMINI-2 experienced flares and did not maintain clear skin
Need for further clinical data and regulatory approval before potential commercialization of imsidolimab
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence of infections, no cases of DRESS or GBS reported, and low incidence of anti-drug antibodies detected
Plan to out-license imsidolimab in 2024 to bring the therapy to patients with GPP
Negative
Some patients who received placebo in GEMINI-2 experienced flares and did not maintain clear skin
Need for further clinical data and regulatory approval before potential commercialization of imsidolimab
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment